Decision analysis approach to risk/benefit evaluation in the ethical review of controlled human infection studies
Risks and benefit evaluation for controlled human infection studies, where healthy volunteers are deliberately exposed to infectious agents to evaluate vaccine efficacy, should be explicit, systematic, thorough, and non-arbitrary. Decision analysis promotes these qualities using four steps: (1) dete...
| Authors: | ; ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
Wiley-Blackwell
[2020]
|
| In: |
Bioethics
Year: 2020, Volume: 34, Issue: 8, Pages: 764-770 |
| IxTheo Classification: | NCH Medical ethics NCJ Ethics of science |
| Further subjects: | B
risk and benefit
B vaccine development B controlled human infection B Decision Analysis B research ethics |
| Online Access: |
Presumably Free Access Volltext (Verlag) Volltext (doi) |
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | 1735929352 | ||
| 003 | DE-627 | ||
| 005 | 20211006145305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201019s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bioe.12773 |2 doi | |
| 035 | |a (DE-627)1735929352 | ||
| 035 | |a (DE-599)KXP1735929352 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Yu, Michael |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Decision analysis approach to risk/benefit evaluation in the ethical review of controlled human infection studies |
| 264 | 1 | |c [2020] | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Risks and benefit evaluation for controlled human infection studies, where healthy volunteers are deliberately exposed to infectious agents to evaluate vaccine efficacy, should be explicit, systematic, thorough, and non-arbitrary. Decision analysis promotes these qualities using four steps: (1) determining explicit criteria and measures for evaluation, (2) identifying alternatives to the study, (3) defining the models used to estimate the measures for each alternative, and (4) running the models to produce the estimates and compare the alternatives. In this paper, we describe how decision analysis might be applied by funders and regulators, as well as by others contemplating the use of novel controlled human infection studies for vaccine development and evaluation. | ||
| 601 | |a Controlling | ||
| 650 | 4 | |a controlled human infection | |
| 650 | 4 | |a Decision Analysis | |
| 650 | 4 | |a research ethics | |
| 650 | 4 | |a risk and benefit | |
| 650 | 4 | |a vaccine development | |
| 652 | |a NCH:NCJ | ||
| 700 | 1 | |a Darton, Thomas C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kimmelman, Jonathan |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioethics |d Oxford [u.a.] : Wiley-Blackwell, 1987 |g 34(2020), 8, Seite 764-770 |h Online-Ressource |w (DE-627)271596708 |w (DE-600)1480658-7 |w (DE-576)078707986 |x 1467-8519 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2020 |g number:8 |g pages:764-770 |
| 856 | |u https://eprints.whiterose.ac.uk/162727/8/1812-hic-outline-v15.pdf |x unpaywall |z Vermutlich kostenfreier Zugang |h repository [oa repository (via OAI-PMH doi match)] | ||
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bioe.12773 |x Verlag |
| 856 | |u https://doi.org/10.1111/bioe.12773 |x doi |3 Volltext | ||
| 936 | u | w | |d 34 |j 2020 |e 8 |h 764-770 |
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 3781837319 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1735929352 | ||
| LOK | |0 005 20211006145305 | ||
| LOK | |0 008 201019||||||||||||||||ger||||||| | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a ixzo | ||
| LOK | |0 936ln |0 1550736558 |a NCH | ||
| LOK | |0 936ln |0 1550736582 |a NCJ | ||
| OAS | |a 1 | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||